Although the signaling pathway for enhanced expression of IGFBP-2 in MS remains unknown, up-regulation of IGF-I and IGF-II, including proinflammatory cytokines, may be responsible for enhanced IGFBP-2 expression in MS. This evidence concerns the gene IGF1 and myeloid sarcoma.